Foundation Medicine and AstraZeneca Announce Genomic Profiling Collaboration

  Foundation Medicine and AstraZeneca Announce Genomic Profiling Collaboration

 Collaboration seeks to enhance clinical trial design by identifying genomic
             predictors of response to targeted cancer therapies

Business Wire

CAMBRIDGE, Mass. -- November 12, 2012

Foundation Medicine, Inc. announced today a multi-year collaboration with
AstraZeneca to identify alterations found in cancer-related tumor genes that
may predict a person’s response or resistance to targeted medicines. Working
with Foundation Medicine to reveal these genomic alterations may help
AstraZeneca to research new medicines for people with cancer. Under the terms
of the collaboration, Foundation Medicine was also granted right of first
negotiation for the development of potential diagnostic products.

Susan Galbraith, Vice President and Head of the AstraZeneca Oncology
Innovative Medicines Unit said, “Our scientific understanding of cancer and
the pathways driving tumour growth enables us to focus on which people are
most likely to respond to our medicines. This collaboration with Foundation
Medicine will help us to identify tumour-specific defects and alterations that
can be used for patient segmentation.”

“AstraZeneca has a strong commitment to understanding the patient-to-patient
variations that may impact the efficacy of therapeutic candidates,” said
Michael J. Pellini, M.D., president and chief executive officer, Foundation
Medicine. “We are helping companies like AstraZeneca achieve deeper insight
into their programs and trials with our unique cancer expertise and our
ability to provide genomic information that can impact clinical treatment
decisions. Together, we expect to enable a more individualized, targeted
approach to cancer drug development and clinical trials.”

About Foundation Medicine

Foundation Medicine is a molecular information company dedicated to a
transformation in cancer care in which treatment is informed by a deep
understanding of the genomic changes that contribute to each patient’s unique
cancer. The company’s initial clinical product, FoundationOne™, is a fully
informative genomic profile to identify a patient’s individual molecular
alterations and match them with relevant targeted therapies and clinical
trials. Foundation Medicine’s molecular information platform aims to improve
day-to-day care for patients by serving the needs of clinicians, academic
researchers and drug developers to help advance the science of molecular
medicine in cancer. For more information, please visit
www.foundationmedicine.com.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a
primary focus on the discovery, development and commercialization of
prescription medicines for gastrointestinal, cardiovascular, neuroscience,
respiratory and inflammation, oncology and infectious disease. AstraZeneca
operates in over 100 countries and its innovative medicines are used by
millions of patients worldwide. For more information please visit:
http://www.astrazeneca.com.

Foundation Medicine^® is a registered trademark, and The Molecular Information
Company™ and FoundationOne™ are trademarks, of Foundation Medicine, Inc.

Contact:

Foundation Medicine
Pure Communications, Inc.
Dan Budwick, 973-271-6085
or
AstraZeneca
Laura Woodin, 302-885-1087
 
Press spacebar to pause and continue. Press esc to stop.